Abstrakti
Successful first diagnostic lumbar puncture (LP) is crucial because intrathecal chemotherapy has not yet protected the central nervous system against cancer cells. If blood contaminates the cerebrospinal fluid (CSF) with blasts, they may enter the central neural system and compromise the patient’s health. We retrospectively determined the incidence of traumatic lumbar punctures (TLP) in 2,507 LPs of 250 pediatric hemato-oncology patients aged from one to 18 years, including both diagnostic and intrathecal treatment procedures, and 2,617 LPs of 1,525 other age-matched pediatric patients. We used ≥10 erythrocytes/µL in the CSF sample as the criterion of TLP. TLPs were less frequent in hemato-oncology patients than in other patients (31.6% vs. 48.5%, p < 0.0001). The incidence of TLP was significantly lower in the first diagnostic LP than in subsequent intrathecal treatment LPs (20.5% vs. 31.6%, p = 0.0046). According to logistic regression analysis, the odds of TLP was 1.6-fold if the LP procedure was not performed in the hemato-oncology department. The odds of the patient’s next LP being traumatic were threefold if the previous first LP was traumatic. A week or less time between the first and next LP tripled the odds of TLP as well. The patient’s age category was not significantly associated with the incidence of TLP. Given the risks of TLP, hemato-oncology patients’ first diagnostic LP should include administration of chemotherapy, as generally recommended, and be performed under general anesthesia or deep sedation by an experienced physician to optimize not only the success of the first LP procedure but also following procedures.
Alkuperäiskieli | Englanti |
---|---|
Julkaisu | PEDIATRIC HEMATOLOGY AND ONCOLOGY |
Vuosikerta | 39 |
Numero | 8 |
DOI - pysyväislinkit | |
Tila | Julkaistu - 2022 |
OKM-julkaisutyyppi | A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä |
Rahoitus
HS, JK, and SH hold shares and are employees of Injeq Oy. All other authors declare no conflicts of interest regarding this study. This study was funded by Injeq Oy, a Finnish startup company that manufactures bioimpedance spinal needle system for lumbar punctures.
Julkaisufoorumi-taso
- Jufo-taso 1
!!ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology